Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GV-58 is a selective N- and P/Q-type Ca2+ channels agonist (EC50: 7.21/8.81 uM for N-type/P-Q-type Ca2+ channel). The inhibitory of GV-58 is 20-fold fewer for CDK kinases activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 47.00 | |
5 mg | In stock | $ 147.00 | |
10 mg | In stock | $ 228.00 | |
25 mg | In stock | $ 455.00 | |
50 mg | In stock | $ 657.00 | |
100 mg | In stock | $ 918.00 | |
500 mg | In stock | $ 1,830.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 162.00 |
Description | GV-58 is a selective N- and P/Q-type Ca2+ channels agonist (EC50: 7.21/8.81 uM for N-type/P-Q-type Ca2+ channel). The inhibitory of GV-58 is 20-fold fewer for CDK kinases activity. |
Targets&IC50 | Ca2+ channel, N-type:7.21 uM, Ca2+ channel, P/Q-type:8.81 uM |
In vitro | In comparison with the parent molecule, (R)-roscovitine, GV-58 has a 20-fold less potent cyclin-dependent kinase antagonist effect, a 3- to 4-fold more potent Ca2+ channel agonist effect, and 4-fold higher efficacy as a Ca2+ channel agonist. GV-58 had no agonist activity (up to 100 μm) on the L-type α-subunit we tested (Cav1.3). |
Molecular Weight | 374.5 |
Formula | C18H26N6OS |
CAS No. | 1402821-41-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (240.32 mM), Sonification is recommended.
Methanol: 55 mg/mL (146.86 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GV-58 1402821-41-3 Membrane transporter/Ion channel Metabolism Calcium Channel Inhibitor Ca channels Ca2+ channels inhibit GV 58 GV58 inhibitor